W
Wail Ba-alawi
Researcher at Princess Margaret Cancer Centre
Publications - 36
Citations - 1614
Wail Ba-alawi is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Pharmacogenomics & Medicine. The author has an hindex of 17, co-authored 29 publications receiving 1058 citations. Previous affiliations of Wail Ba-alawi include University Health Network & King Abdullah University of Science and Technology.
Papers
More filters
Journal ArticleDOI
Effects of cytosine methylation on transcription factor binding sites
Yulia A. Medvedeva,Abdullah M. Khamis,Ivan V. Kulakovskiy,Ivan V. Kulakovskiy,Wail Ba-alawi,Shariful Islam Bhuyan,Hideya Kawaji,Timo Lassmann,Matthias Harbers,Alistair R. R. Forrest,Vladimir B. Bajic +10 more
TL;DR: The results indicate that direct and selective methylation of certain TFBS that prevents TF binding is restricted to special cases and cannot be considered as a general regulatory mechanism of transcription.
Journal ArticleDOI
HOCOMOCO: expansion and enhancement of the collection of transcription factor binding sites models
Ivan V. Kulakovskiy,Ivan V. Kulakovskiy,Ilya E. Vorontsov,Ivan S. Yevshin,Anastasiia V. Soboleva,Artem S. Kasianov,Haitham Ashoor,Wail Ba-alawi,Vladimir B. Bajic,Yulia A. Medvedeva,Fedor A. Kolpakov,Vsevolod J. Makeev,Vsevolod J. Makeev,Vsevolod J. Makeev +13 more
TL;DR: The expanded and enhanced version of HOCOMOCO now provides position weight matrix (PWM) models for binding sites of 601 human TFs and, in addition, PWMs for 396 mouse TFs, and introduces the largest up to date collection of dinucleotide PWM models for 86 (52) human (mouse) TFs.
Journal ArticleDOI
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies.
Petr Smirnov,Petr Smirnov,Victor Kofia,Alexander Maru,Mark Freeman,Chantal Ho,Nehme El-Hachem,George Alexandru Adam,George Alexandru Adam,Wail Ba-alawi,Wail Ba-alawi,Zhaleh Safikhani,Zhaleh Safikhani,Benjamin Haibe-Kains +13 more
TL;DR: How the curation of cell line and chemical compound identifiers maximizes the overlap between datasets is described and how users can leverage such data to compare and extract robust drug phenotypes is described.
Journal ArticleDOI
ONECUT2 is a driver of neuroendocrine prostate cancer.
Haiyang Guo,Xinpei Ci,Xinpei Ci,Musaddeque Ahmed,Junjie Tony Hua,Junjie Tony Hua,Fraser Soares,Dong Lin,Dong Lin,Loredana Puca,Aram Vosoughi,Hui Xue,Hui Xue,Estelle Li,Peiran Su,Peiran Su,Sujun Chen,Sujun Chen,Tran Nguyen,Yi Liang,Yuzhe Zhang,Yuzhe Zhang,Yuzhe Zhang,Xin Xu,Jing Xu,Anjali V. Sheahan,Wail Ba-alawi,Wail Ba-alawi,Si Zhang,Osman Mahamud,Osman Mahamud,Ravi N. Vellanki,Martin E. Gleave,Robert G. Bristow,Robert G. Bristow,Benjamin Haibe-Kains,John T. Poirier,Charles M. Rudin,Ming-Sound Tsao,Ming-Sound Tsao,Bradly G. Wouters,Bradly G. Wouters,Ladan Fazli,Felix Y. Feng,Leigh Ellis,Leigh Ellis,Theo H. van der Kwast,Theo H. van der Kwast,Alejandro Berlin,Alejandro Berlin,Marianne Koritzinsky,Marianne Koritzinsky,Paul C. Boutros,Paul C. Boutros,Amina Zoubeidi,Himisha Beltran,Yuzhuo Wang,Yuzhuo Wang,Housheng Hansen He,Housheng Hansen He +59 more
TL;DR: ONECUT2 is reported to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumorHypoxia directed therapy to be effective in NEPC is found, highlighting the potential of Hypoxia-directed therapy for NEPC patients.
Journal ArticleDOI
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Qin Wu,Qin Wu,Qin Wu,Wail Ba-alawi,Wail Ba-alawi,Geneviève Deblois,Jennifer Cruickshank,Shili Duan,Evelyne Lima-Fernandes,Evelyne Lima-Fernandes,Jillian Haight,Seyed Ali Madani Tonekaboni,Seyed Ali Madani Tonekaboni,Anne-Marie Fortier,Hellen Kuasne,Trevor D. McKee,Hassan Mahmoud,Hassan Mahmoud,Hassan Mahmoud,Michelle Kushida,Sarina Cameron,Sarina Cameron,Nergiz Dogan-Artun,Nergiz Dogan-Artun,Wenjun Chen,Yan Nie,Yan Nie,Yan Nie,Lan Xin Zhang,Ravi N. Vellanki,Stanley Zhou,Stanley Zhou,Panagiotis Prinos,Bradly G. Wouters,Bradly G. Wouters,Peter B. Dirks,Susan J. Done,Morag Park,David W. Cescon,Benjamin Haibe-Kains,Mathieu Lupien,Mathieu Lupien,Cheryl H. Arrowsmith,Cheryl H. Arrowsmith,Cheryl H. Arrowsmith +44 more
TL;DR: The authors show the efficacy of GLUT1 pharmacological inhibition against a subset of tumors expressing RB1, thereby identifying RB1 protein level as a biomarker of sensitivity to anti-GLUT1 therapy and highlighting a strong and targetable RB1-GLut1 metabolic axis in TNBC.